- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02558777
Pilot Study of a Multicomponent Nurse Intervention to Reduce Delirium in Hospitalized Older Adults (MID-Nurse-P)
Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P
Objectives: To analyze if a multicomponent nurse-led intervention randomized clinical trial (MID-Nurse Study) is feasible (Pilot study), and can reduce the incidence, duration, and severity of delirium in hospitalized older adults in an AGU.
Design: Parallel-group Double-blind Randomized Clinical Trial (Pilot Study). Setting: AGU "Complejo Hospitalario Universitario from Albacete" (Albacete, Spain).
Participants: 50 patients ≥ 65 years hospitalized in the AGU (21 intervention group, 29 control group).
Interventions: After risk factor analysis, all participants in the intervention group (IG) received a daily multicomponent intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain) by the intervention nurses. The control group (CG) received usual care.
Measurements: Delirium presence was determined daily with the Confusion Assessment Method (CAM), and delirium severity with the Delirium Rating Scale-Revised-98 (DRS). Mortality, days of hospitalization, use of physical restraint measures, and use of drugs for delirium control (neuroleptics and benzodiacepines) were also recorded.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Parallel-group, double blind (evaluation and analysis), randomized clinical trial (pilot study). The design was based on recommendations for conducting pilot studies (Thabane 2010).
The main objective of the MID-Nurse (Randomized Clinical Trial) was to analyze if a multicomponent nurse-led intervention reduces the incidence, duration, and severity of delirium in hospitalized older adults in an Acute Geriatric Unit (AGU).
Specific objectives and evaluating criteria of the MID-Nurse-P (Pilot Study) were:
- Process: To determine the recruitment rate (criteria: at least 70% of the eligible patients can be recruited), the complete follow-up rate (criteria: at least 85% of the included participants complete the follow-up), and the adherence to intervention (criteria: at least 80% of the included participants receive every scheduled intervention).
- Resources: To assess capacity of the team and process time to conduct the trial. Criteria: Less than 10% of the participants can´t complete the intervention program due to study team problems, and daily time employed per participant is not longer than 30 minutes.
- Management: To analyze potential study personnel and data managing problems.
- Scientific: To estimate the intervention effect and the variance.
In the first 24 hours from admission, all the following data were collected by the evaluation nurses, once the informed consent was signed, and randomization performed by the principal investigator, who did not take part in the rest of the data collection and clinical intervention: Demographic data, Charlson comorbidity index, mean clinical diagnosis for admission, usually consumed drugs before admission, Barthel index, Holden´s FAC instrument, Pfeiffer´s Short Portable Mental Status Questionnaire, Reisberg´s Global Deterioration Scale, Dowton scale, pain with the visual analogical scale, and pressure ulcers risk with the Braden scale. Vital signs were determined on admission, including blood pressure, heart rate, temperature, hydration level, and oxygen saturation. Medical or nurse procedures were recorded, including bladder catheterization, nasogastric tube placement, venous or arterial access, blood sample acquisition, and other invasive procedures.
Blood sample was collected, and haemoglobin, leukocyte and neutrophil count, reactive C protein, sedimentation rate, glucose, urea, sodium, potassium, albumin, total proteins, cholesterol, thyroid stimulating hormone, transferrin, ferritin, total iron, folic acid, and B12 vitamin, were recorded.
After patient enrollment, all the patients received daily an evaluation of the Confusion Assessment Method scale (CAM) (Inouye 1990) by the evaluation nurses, in the afternoon. Prevalence of delirium throughout the follow-up was described, prevalence excluding the first day (to avoid bias of patients that were admitted with confusion), and incidence of delirium (new case across the follow-up, one patient could have more than 1 incident delirium). Number of days with delirium were also registered, and mean number of days with delirium was calculated for both groups.
In the case that the CAM was positive for delirium, patients also were evaluated with the Delirium Rating Scale-Revised-98 (DRS-R-98) (de Rooij 2006) to determine delirium severity. Total delirium severity was calculated by adding the severity of delirium during all days of hospitalization, and mean severity per day was calculated dividing the global severity per number of days with delirium.
Main outcome variables were the presence of delirium throughout the follow-up (dichotomic variable, yes/no), number of days with delirium during hospitalization (continuous variable), and total delirium severity (sum of DRS-R-98 during the complete follow-up).
Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. Participants in the control group received usual medical and nurse care during all the hospitalization process. The intervention was carried out exclusively by the "intervention nurses", and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Albacete, Spain, 02006
- Complejo Hospitalario Universitario de Albacete
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with an age equal or older than 65 years
- Hospitalized at the Acute Geriatric Unit of the "Complejo Hospitalario Universitario of Albacete"
- Valid signed informed consent by the patient or legal representative.
Exclusion Criteria:
- Agonic situation
- Non-Spanish speaking
- Severe cognitive decline (Reisberg´s Global Deterioration Scale = 7)
- Patients sharing the same room with a previously included participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control Group
Usual care
|
|
|
Experimental: Intervention Group
Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
|
Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge.
The intervention was carried out exclusively by the "intervention nurses", and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain).
Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Delirium incidence (% participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Delirium incidence during hospitalization (% participants)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean daily delirium severity (mean score Delirium Rating Scale-Revised-98)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Mean delirium severity per day with delirium (mean score Delirium Rating Scale-Revised-98)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Mortality (% of participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Mortality (% of participants)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Length of stay (days)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Length of hospitalization time (days)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Restraint measures (number of participants with these measures)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Use of restraint measures for delirium control (number of participants with these measures)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Drugs for delirium (% of participants using neuroleptics or benzodiazepines)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Use of drugs (neuroleptics or benzodiazepines) for delirium control (% of participants)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Delirium prevalence (% of participants)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Delirium prevalence during hospitalization (% of participants)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Delirium severity (sum of total Delirium Rating Scale-Revised-98 socres during hospitalization)
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
Delirium severity during hospitalization (sum of total Delirium Rating Scale-Revised-98 socres during hospitalization)
|
Participants will be followed for the duration of hospital stay, an expected average of 2 weeks
|
|
Recruitment rate (% of patients)
Time Frame: Up to five months
|
% of the eligible patients recruited
|
Up to five months
|
|
Complete follow-up rate (% of participants)
Time Frame: Up to five months
|
% of the included participants completing the follow-up
|
Up to five months
|
|
Adherence to intervention (% of participants)
Time Frame: Up to five months
|
% of included participants receiving every scheduled intervention
|
Up to five months
|
|
Capacity of the team (% of participants)
Time Frame: Up to five months
|
% of participants that can´t complete the intervention program due to study team problems
|
Up to five months
|
|
Process time (time in minutes)
Time Frame: Up to five months
|
Daily time employed per participant for delivering the intervention
|
Up to five months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Pedro Abizanda, MD,PhD, Complejo Hospitalario Universitario de Albacete (SESCAM)
Publications and helpful links
General Publications
- Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014 Mar 8;383(9920):911-22. doi: 10.1016/S0140-6736(13)60688-1. Epub 2013 Aug 28.
- Vidan MT, Sanchez E, Alonso M, Montero B, Ortiz J, Serra JA. An intervention integrated into daily clinical practice reduces the incidence of delirium during hospitalization in elderly patients. J Am Geriatr Soc. 2009 Nov;57(11):2029-36. doi: 10.1111/j.1532-5415.2009.02485.x. Epub 2009 Sep 15.
- Hshieh TT, Yue J, Oh E, Puelle M, Dowal S, Travison T, Inouye SK. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015 Apr;175(4):512-20. doi: 10.1001/jamainternmed.2014.7779. Erratum In: JAMA Intern Med. 2015 Apr;175(4):659.
- Siddiqi N, Stockdale R, Britton AM, Holmes J. Interventions for preventing delirium in hospitalised patients. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005563. doi: 10.1002/14651858.CD005563.pub2.
- Avendano-Cespedes A, Garcia-Cantos N, Gonzalez-Teruel Mdel M, Martinez-Garcia M, Villarreal-Bocanegra E, Oliver-Carbonell JL, Abizanda P. Pilot study of a preventive multicomponent nurse intervention to reduce the incidence and severity of delirium in hospitalized older adults: MID-Nurse-P. Maturitas. 2016 Apr;86:86-94. doi: 10.1016/j.maturitas.2016.02.002. Epub 2016 Feb 8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MID-Nurse-P
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delirium
-
Alexandria UniversityCompletedClozapine Poisoning | Hypoactive Delirium | Tricyclic Antidepressant Poisoning | Anticholinergic Delirium | Antipsychotic Toxicity | CNS Depression | Procyclidine Induced DeliriumEgypt
-
Efficacy Care R&D LtdHadassah Medical OrganizationUnknownDelirium | Delirium, Cause Unknown | Delirium of Mixed Origin | Delirium Confusional State | Delirium Drug-InducedIsrael
-
Duke UniversityNot yet recruitingDelirium Confusional State | Hyperactive Delirium | Delirium in the Intensive Care Unit | Agitated DeliriumUnited States
-
Sengkang General HospitalRecruitingDelirium and Post-operative Cognitive Dysfunction (POCD) | Delirium, Postoperative | Delirium - PostoperativeSingapore
-
Imperial College Healthcare NHS TrustRecruitingCardiac Surgery | Intensive Care Unit Delirium | Post Operative DeliriumUnited Kingdom
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicCompletedDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Universitat de LleidaHospital d'IgualadaNot yet recruitingDelirium in Old Age | Delirium Treatment | Delirium Confusional StateSpain
-
Universidad de SantanderUnknownDelirium of Mixed Origin | Hypoactive Delirium | Hyperactive DeliriumColombia
-
Wonkwang University HospitalCompleted
-
Second Affiliated Hospital of Wenzhou Medical UniversityAffiliated Wenling Hospital of Wenzhou Medical UniversityRecruitingInjection | Delirium in Old Age | Post Operative Delirium | Non-cardiac SurgeryChina
Clinical Trials on Multicomponent nurse-led intervention
-
Assistance Publique - Hôpitaux de ParisCompletedRheumatoid Arthritis (RA) | Spondyloarthritis (SpA)France
-
Hellenic Mediterranean UniversityRecruiting
-
Fujian Cancer HospitalNot yet recruitingNasopharyngeal Carcinoma
-
Hellenic Mediterranean UniversityCompletedGlaucoma | Health Literacy | Patient ActivationGreece
-
Dokuz Eylul UniversityCompleted
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)CompletedBreast Cancer | PreDiabetes | Type 2 DiabetesUnited States
-
Texas Woman's UniversityNot yet recruiting
-
University of UtahCompletedPain | Osteoarthritis, Knee | Osteoarthritis, HipUnited States
-
YU LONG HONGCompletedHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and NeckTaiwan